{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T07:35:19Z","timestamp":1792222519263,"version":"4.4.0"},"reference-count":129,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Mpox (earlier known as monkeypox) virus infection is a recognized public health emergency. There has been little research on the treatment options. This article reviews the specific drugs used to treat mpox virus infection and the vaccines used here. Instead of focusing on the mechanistic basis, this review narrates the practical, real-life experiences of individual patients of mpox virus disease being administered these medicines. We conducted a bibliometric analysis on the treatment of the mpox virus using data from several databases like PubMed, Scopus, and Embase. The research on this topic has grown tremendously recently but it is highly concentrated in a few countries. Cidofovir is the most studied drug. This is because it is indicated and also used off-label for several conditions. The drugs used for mpox virus infection include tecovirimat, cidofovir, brincidofovir, vaccinia immune globulin, and trifluridine. Tecovirimat is used most frequently. It is a promising option in progressive mpox disease in terms of both efficacy and safety. Brincidofovir has been associated with treatment discontinuation due to elevated hepatic enzymes. Cidofovir is also not the preferred drug, often used because of the unavailability of tecovirimat. Trifluridine is used topically as an add-on agent along with tecovirimat for ocular manifestations of mpox virus disease. No study reports individual patient data for vaccinia immune globulin. Though no vaccine is currently approved for mpox virus infection, ACAM 2000 and JYNNEOS are the vaccines being mainly considered. ACAM 2000 is capable of replicating and may cause severe adverse reactions. It is used when JYNNEOS is contraindicated. Several drugs and vaccines are under development and have been discussed alongside pragmatic aspects of mpox virus treatment and prevention. Further studies can provide more insight into the safety and efficacy of Tecovirimat in actively progressing mpox virus disease.<\/jats:p>","DOI":"10.3389\/fphar.2023.1149909","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T04:39:57Z","timestamp":1683261597000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":45,"title":["Pharmacological treatment and vaccines in monkeypox virus: a narrative review and bibliometric analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Muhammad Aaqib","family":"Shamim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakisini","family":"Satapathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijaya Kumar","family":"Padhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Dutt","family":"Veeramachaneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naushaba","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anindita","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhimanyu","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aroop","family":"Mohanty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keerti Bhusan","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Kabir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali A.","family":"Rabaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawaher","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab A.","family":"Al Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab Ahmed","family":"Alsoliabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Al Fraij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit","family":"Sah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso J.","family":"Rodriguez-Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jinf.2022.09.002","article-title":"Repurposing antiviral drugs against the human monkeypox virus DNA-dependent RNA polymerase; in silico perspective","volume":"85","author":"Abduljalil","year":"2022","journal-title":"J. Infect."},{"key":"B2","doi-asserted-by":"publisher","first-page":"102094","DOI":"10.1016\/j.eujim.2021.102094","article-title":"Traditional medicinal plants used for treating emerging and re-emerging viral diseases in northern Nigeria","volume":"49","author":"Abubakar","year":"2022","journal-title":"Eur. J. Integr. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S1473-3099(22)00228-6","article-title":"Clinical features and management of human monkeypox: A retrospective observational study in the UK","volume":"22","author":"Adler","year":"2022","journal-title":"Lancet. Infect. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"985450","DOI":"10.3389\/fimmu.2022.985450","article-title":"Multi-epitope chimeric vaccine design against emerging Monkeypox virus via reverse vaccinology techniques-a bioinformatics and immunoinformatics approach","volume":"13","author":"Aiman","year":"2022","journal-title":"Front. Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e01587","DOI":"10.1016\/j.idcr.2022.e01587","article-title":"Monkeypox - an emerging pandemic","volume":"29","author":"Ajmera","year":"2022","journal-title":"IDCases"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1157627","DOI":"10.3389\/fcimb.2023.1157627","article-title":"Anti-viral drug discovery against monkeypox and smallpox infection by natural curcumin derivatives: A computational drug design approach","volume":"13","author":"Akash","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"502485","DOI":"10.1101\/2022.08.02.502485","article-title":"Potential anti-monkeypox virus activity of atovaquone, mefloquine, and molnupiravir, and their potential use as treatments","volume":"2022","author":"Akazawa","year":"2022","journal-title":"BioRxiv"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.3390\/v14112374","article-title":"Immunoinformatics-aided design of a peptide based multiepitope vaccine targeting glycoproteins and membrane proteins against monkeypox virus","volume":"14","author":"Akhtar","year":"2022","journal-title":"Viruses"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e2444","DOI":"10.1002\/rmv.2444","article-title":"Effect of prior immunisation with smallpox vaccine for protection against human monkeypox: A systematic review","volume":"2022","author":"Akter","year":"2023","journal-title":"Rev. Med. Virology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.3390\/v14091870","article-title":"A glance at the development and patent literature of tecovirimat: The first-in-class therapy for emerging monkeypox outbreak","volume":"14","author":"Almehmadi","year":"2022","journal-title":"Viruses"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3390\/ph15091129","article-title":"Fludarabine, a potential DNA-dependent RNA polymerase inhibitor, as a prospective drug against monkeypox virus: A computational approach","volume":"15","author":"Altayb","year":"2022","journal-title":"Pharm. (Basel, Switz."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1136\/bjo.83.10.1153","article-title":"Anterior uveitis associated with intravenous cidofovir use in patients with cytomegalovirus retinitis","volume":"83","author":"Ambati","year":"1999","journal-title":"Br. J. Ophthalmol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.jiph.2023.03.004","article-title":"Molecular docking of monkeypox (mpox) virus proteinase with FDA approved lead molecules","volume":"16","author":"Arasu","year":"2023","journal-title":"J. Infect. Public Health"},{"key":"B14","unstructured":"Australian human monkeypox treatment guidelines2022"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1004804","DOI":"10.3389\/fimmu.2022.1004804","article-title":"Contriving multi-epitope vaccine ensemble for monkeypox disease using an immunoinformatics approach","volume":"13","author":"Aziz","year":"2022","journal-title":"Front. Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.otorri.2019.11.001","article-title":"Trends in recurrent respiratory papillomatosis treatment","volume":"72","author":"Ballestas","year":"2021","journal-title":"Acta Otorrinolaringol. Espanola"},{"key":"B17","doi-asserted-by":"publisher","first-page":"20499361221138349","DOI":"10.1177\/20499361221138349","article-title":"Monkeypox infection and resolution after treatment with tecovirimat in two patients with HIV disease","volume":"9","author":"Beatty","year":"2022","journal-title":"Ther. Adv. Infect. Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e0286222","DOI":"10.1128\/mbio.02862-22","article-title":"The potential role of passive antibody-based therapies as treatments for monkeypox","volume":"13","author":"Bloch","year":"2022","journal-title":"MBio"},{"key":"B19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2165\/00003495-198223050-00001","article-title":"Trifluridine: A review of its antiviral activity and therapeutic use in the topical treatment of viral eye infections","volume":"23","author":"Carmine","year":"1982","journal-title":"Trifluridine. Drugs"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.15585\/mmwr.mm7142e1","article-title":"Ocular monkeypox - United States, july-september 2022","volume":"71","author":"Cash-Goldwasser","year":"2022","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"B21","unstructured":"Expanded access IND protocol: Use of tecovirimat (TPOXX\u00ae) for treatment of human non-Variola orthopoxvirus infections in adults and children"},{"key":"B22","unstructured":"Interim clinical guidance for the treatment of monkeypox"},{"key":"B23","unstructured":"Monkeypox - clinical treatment"},{"key":"B24","doi-asserted-by":"publisher","first-page":"109346","DOI":"10.1016\/j.intimp.2022.109346","article-title":"Monkeypox virus vaccine evolution and global preparedness for vaccination","volume":"113","author":"Chakraborty","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e01925","DOI":"10.1128\/AAC.01925-18","article-title":"Cidofovir diphosphate inhibits adenovirus 5 DNA polymerase via both nonobligate chain termination and direct inhibition, and polymerase mutations confer cidofovir resistance on intact virus","volume":"63","author":"Chamberlain","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e27892","DOI":"10.1002\/jmv.27892","article-title":"Bibliometric analysis of global research trends on monkeypox: Are we ready to face this challenge?","volume":"95","author":"Cheng","year":"2022","journal-title":"J. Med. Virology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1086\/314487","article-title":"In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first\u2010 or second\u2010line cidofovir therapy: Relationship to clinical outcome","volume":"178","author":"Cherrington","year":"1998","journal-title":"J. Infect. Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1016\/S1473-3099(22)00741-1","article-title":"Monkeypox encephalitis with transverse myelitis in a female patient","volume":"23","author":"Cole","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2165\/00003088-199936020-00004","article-title":"Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir","volume":"36","author":"Cundy","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"B30","volume-title":"Chapter 12 - herpesvirus polymerase inhibitors","author":"Das","year":"2019"},{"key":"B31","doi-asserted-by":"publisher","first-page":"02066","DOI":"10.1039\/d2bm02066a","article-title":"Advances in nanomedicine for the treatment of infectious diseases caused by viruses","volume":"2023","author":"Dash","year":"2023","journal-title":"Biomaterials Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1128\/CMR.16.4.569-596.2003","article-title":"Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections","volume":"16","author":"de Clercq","year":"2003","journal-title":"Clin. Microbiol. Rev."},{"key":"B33","doi-asserted-by":"publisher","first-page":"102528","DOI":"10.1016\/j.tmaid.2022.102528","article-title":"Therapeutic strategies for human poxvirus infections: Monkeypox (mpox), smallpox, molluscipox, and orf","volume":"52","author":"De Clercq","year":"2022","journal-title":"Travel Med. Infect. Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e0122622","DOI":"10.1128\/aac.01226-22","article-title":"New perspectives on antimicrobial agents: Tecovirimat for treatment of human monkeypox virus","volume":"66","author":"DeLaurentis","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1001\/jama.2022.15336","article-title":"Compassionate use of tecovirimat for the treatment of monkeypox infection","volume":"328","author":"Desai","year":"2022","journal-title":"JAMA"},{"key":"B36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1128\/AAC.01601-13","article-title":"KAY-2-41, a novel nucleoside analogue inhibitor of orthopoxviruses in vitro and in vivo","volume":"58","author":"Duraffour","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1177\/135965350701200802","article-title":"Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures","volume":"12","author":"Duraffour","year":"2007","journal-title":"Antivir. Ther."},{"key":"B38","doi-asserted-by":"publisher","first-page":"jcb30397","DOI":"10.1002\/jcb.30397","article-title":"Drug repurposing for Mpox: Discovery of small molecules as potential inhibitors against DNA-dependent RNA polymerase using molecular modeling approach","volume":"2023","author":"Dutt","year":"2023","journal-title":"J. Cell. Biochem."},{"key":"B39","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jdcr.2021.05.001","article-title":"Treatment of acyclovir-resistant herpes simplex virus with intralesional cidofovir","volume":"13","author":"Enescu","year":"2021","journal-title":"JAAD Case Rep."},{"key":"B40","unstructured":"Tecovirimat SIGA2021"},{"key":"B41","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s15010-022-01949-x","article-title":"Cidofovir for treating complicated monkeypox in a man with acquired immune deficiency syndrome","volume":"51","author":"Fabrizio","year":"2022","journal-title":"Infection"},{"key":"B42","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.nefroe.2020.02.006","article-title":"Intravesical cidofovir, use in BK polyomavirus-associated haemorrhagic cystitis after haematopoietic stem cell transplantation: Off-label","volume":"41","author":"Ferrer","year":"2021","journal-title":"Nefrologia"},{"key":"B43","unstructured":"FDA approves the first drug with an indication for treatment of smallpox2018"},{"key":"B44","unstructured":"Highlights of prescribing information - tecovirimat2022"},{"key":"B45","unstructured":"Highlights of prescribing information: ACAM20002007"},{"key":"B46","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3390\/pathogens12030452","article-title":"Ophthalmic manifestations of the monkeypox virus: A systematic review and meta-analysis","volume":"12","author":"Gandhi","year":"2023","journal-title":"Pathogens"},{"key":"B47","doi-asserted-by":"publisher","first-page":"101817","DOI":"10.1016\/j.eclinm.2022.101817","article-title":"Oral manifestation of the monkeypox virus: A systematic review and meta-analysis","volume":"56","author":"Gandhi P","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B48","doi-asserted-by":"publisher","first-page":"8424","DOI":"10.1073\/pnas.1810398115","article-title":"Structural basis for the inhibition of poxvirus assembly by the antibiotic rifampicin","volume":"115","author":"Garriga","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B49","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2217\/fvl.11.27","article-title":"Development of the small-molecule antiviral ST-246 as a smallpox therapeutic","volume":"6","author":"Grosenbach","year":"2011","journal-title":"Future Virol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2022.18320","article-title":"Human monkeypox virus infection in the immediate period after receiving modified vaccinia Ankara vaccine","volume":"328","author":"Hazra","year":"2022","journal-title":"JAMA"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1016\/S0140-6736(22)01528-8","article-title":"Human monkeypox virus infection in an immunocompromised man: Trial with tecovirimat","volume":"400","author":"Hernandez","year":"2022","journal-title":"Lancet"},{"key":"B52","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1086\/422999","article-title":"Clinical efficacy of intramuscular vaccinia immune globulin: A literature review","volume":"39","author":"Hopkins","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s40265-018-0967-6","article-title":"Tecovirimat: First global approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"B54","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41392-022-01215-4","article-title":"Monkeypox: Epidemiology, pathogenesis, treatment and prevention","volume":"7","author":"Huang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.3390\/biomedicines11041106","article-title":"VP37 protein inhibitors for mpox treatment: Highlights on recent advances, patent literature, and future directions","volume":"11","author":"Hudu","year":"2023","journal-title":"Biomedicines"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.3390\/life12101590","article-title":"Monkeypox: An emerging global public health emergency","volume":"12","author":"Jeyaraman","year":"2022","journal-title":"Life (Basel, Switz."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e26531","DOI":"10.7759\/cureus.26531","article-title":"Monkeypox: A comprehensive review of transmission, pathogenesis, and manifestation","volume":"14","author":"Kaler","year":"2022","journal-title":"Cureus"},{"key":"B58","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1080\/14760584.2023.2198600","article-title":"Monkeypox pandemic containment: Does the ACAM2000 vaccine play a role in the current outbreaks?","volume":"22","author":"Katamesh","year":"2023","journal-title":"Expert Rev. Vaccines"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1116988","DOI":"10.3389\/fimmu.2023.1116988","article-title":"Deciphering the complete human-monkeypox virus interactome: Identifying immune responses and potential drug targets","volume":"14","author":"Kataria","year":"2023","journal-title":"Front. Immunol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/jac\/dkm143","article-title":"Simultaneous development of Fanconi syndrome and acute renal failure associated with cidofovir","volume":"60","author":"Kazory","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1345\/aph.17312","article-title":"Cidofovir in the treatment of cytomegaloviral disease","volume":"32","author":"Kendle","year":"1998","journal-title":"Ann. Pharmacother."},{"key":"B62","doi-asserted-by":"publisher","first-page":"106797","DOI":"10.1016\/j.compbiomed.2023.106797","article-title":"Structure-based design of promising natural products to inhibit thymidylate kinase from Monkeypox virus and validation using free energy calculations","volume":"158","author":"Khan","year":"2023","journal-title":"Comput. Biol. Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2165\/00003495-199652020-00006","volume":"52","author":"Lea","year":"1996","journal-title":"Cidofovir. Drugs"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.7326\/L22-0300","article-title":"Monkeypox virus-associated severe proctitis treated with oral tecovirimat: A report of two cases","volume":"175","author":"Lucar","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.cmi.2022.08.012","article-title":"Clinical characteristics of ambulatory and hospitalised patients with monkeypox virus infection: An observational cohort study","volume":"29","author":"Mailhe","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e01626","DOI":"10.1016\/j.idcr.2022.e01626","article-title":"Severe monkeypox with superimposed bacterial infection in an immunocompetent patient: A case report","volume":"30","author":"Manoharan","year":"2022","journal-title":"IDCases"},{"key":"B67","doi-asserted-by":"publisher","first-page":"ofac377","DOI":"10.1093\/ofid\/ofac377","article-title":"Tecovirimat for the treatment of human monkeypox: An initial series from Massachusetts, United States","volume":"9","author":"Matias","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1099\/jgv.0.000422","article-title":"New effective chemically synthesized anti-smallpox compound NIOCH-14","volume":"97","author":"Mazurkov","year":"2016","journal-title":"J. General Virology"},{"key":"B69","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s10517-020-05034-x","article-title":"Estimation of absolute bioavailability of the chemical substance of the anti-smallpox preparation NIOCH-14 in mice","volume":"170","author":"Mazurkov","year":"2020","journal-title":"Bull. Exp. Biol. Med."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1101\/2022.08.24.22279177","article-title":"Monkeypox treatment with tecovirimat in the Central African Republic under an expanded access programme","author":"Mbrenga","year":"2022"},{"key":"B71","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1080\/14787210.2017.1328279","article-title":"Drug development challenges and strategies to address emerging and resistant fungal pathogens","volume":"15","author":"McCarthy","year":"2022","journal-title":"Expert Rev. Anti-Infective Ther."},{"key":"B72","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jinf.2022.11.001","article-title":"Clinical experience with use of oral Tecovirimat or Intravenous Cidofovir for the treatment of Monkeypox in an Italian reference hospital","volume":"86","author":"Mondi","year":"2022","journal-title":"J. Infect."},{"key":"B73","doi-asserted-by":"publisher","first-page":"102417","DOI":"10.1016\/j.tmaid.2022.102417","article-title":"Hospitalisation for monkeypox in milan, Italy","volume":"49","author":"Moschese","year":"2022","journal-title":"Travel Med. Infect. Dis."},{"key":"B74","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2147\/dddt.s3687","article-title":"ACAM2000: The new smallpox vaccine for United States strategic national stockpile","volume":"4","author":"Nalca","year":"2010","journal-title":"Drug Des. Dev. Ther."},{"key":"B75","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1177\/13596535211059889","article-title":"Topical cidofovir for benign human papillomavirus-associated skin lesions","volume":"26","author":"Napolitano","year":"2021","journal-title":"Antivir. Ther."},{"key":"B76","unstructured":"PubChem compound summary for CID 483477, brincidofovir2022"},{"key":"B77","doi-asserted-by":"publisher","first-page":"105254","DOI":"10.1016\/j.jcv.2022.105254","article-title":"Clinical characteristics and comparison of longitudinal qPCR results from different specimen types in a cohort of ambulatory and hospitalized patients infected with monkeypox virus","volume":"155","author":"N\u00f6rz","year":"2022","journal-title":"J. Clin. Virology"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.15585\/mmwr.mm7137e1","article-title":"Clinical use of tecovirimat (tpoxx) for treatment of monkeypox under an investigational new drug protocol - United States, may-august 2022","volume":"71","author":"O\u2019Laughlin","year":"2022","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"B79","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3390\/tropicalmed7110369","article-title":"Antiviral treatment against monkeypox: A scoping review","volume":"7","author":"Ortiz-Saavedra","year":"2022","journal-title":"Trop. Med. Infect. Dis."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.15585\/mmwr.mm7138e1","article-title":"Two cases of monkeypox-associated encephalomyelitis - Colorado and the District of Columbia, july-august 2022","volume":"71","author":"Pastula","year":"2022","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"B81","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1159\/000322101","article-title":"Orthopox viruses: Infections in humans","volume":"37","author":"Pauli","year":"2010","journal-title":"Transfus. Med. Hemotherapy"},{"key":"B82","doi-asserted-by":"publisher","first-page":"101779","DOI":"10.1016\/j.ajoc.2022.101779","article-title":"Treatment of ocular-involving monkeypox virus with topical trifluridine and oral tecovirimat in the 2022 monkeypox virus outbreak","volume":"29","author":"Perzia","year":"2023","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1016\/j.joms.2022.07.147","article-title":"Oral manifestations of monkeypox: A report of 2 cases","volume":"80","author":"Peters","year":"2022","journal-title":"J. Oral Maxillofac. Surg."},{"key":"B84","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.antiviral.2019.01.011","article-title":"Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance","volume":"163","author":"Piret","year":"2019","journal-title":"Antivir. Res."},{"key":"B85","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2174\/1568005053174627","article-title":"Orthopoxvirus targets for the development of antiviral therapies","volume":"5","author":"Prichard","year":"2005","journal-title":"Curr. Drug Targets. Infect. Disord."},{"key":"B86","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.antiviral.2012.02.012","article-title":"Orthopoxvirus targets for the development of new antiviral agents","volume":"94","author":"Prichard","year":"2012","journal-title":"Antivir. Res."},{"key":"B87","doi-asserted-by":"publisher","first-page":"e28306","DOI":"10.1002\/jmv.28306","article-title":"Monkeypox outbreak 2022: What we know so far and its potential drug targets and management strategies","volume":"95","author":"Rabaan","year":"2023","journal-title":"J. Med. Virology"},{"key":"B88","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jinf.2022.07.022","article-title":"Monkeypox infection among men who have sex with men: PCR testing on seminal fluids","volume":"85","author":"Raccagni","year":"2022","journal-title":"J. Infect."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1001\/jamaophthalmol.2022.4568","article-title":"Ocular pox lesions in a male patient with monkeypox treated with tecovirimat","volume":"140","author":"Rai","year":"2022","journal-title":"JAMA Ophthalmol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"232","DOI":"10.15585\/mmwr.mm7209a4","article-title":"Interim clinical treatment considerations for severe manifestations of mpox - United States, february 2023","volume":"72","author":"Rao","year":"2023","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"B91","doi-asserted-by":"publisher","first-page":"509","DOI":"10.15585\/MMWR.MM7114A1","article-title":"Monkeypox in a traveler returning from Nigeria - dallas, Texas, july 2021","volume":"71","author":"Rao","year":"2022","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.4065\/mcp.2011.0309","article-title":"Antiviral drugs for viruses other than human immunodeficiency virus","volume":"86","author":"Razonable","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"B93","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.medcle.2023.01.005","article-title":"Vaccines against monkeypox","volume":"160","author":"Reina","year":"2023","journal-title":"Med. Clin. Engl. Ed.)"},{"key":"B94","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3390\/v9120380","article-title":"Improving the care and treatment of monkeypox patients in low-resource settings: Applying evidence from contemporary biomedical and smallpox biodefense research","volume":"9","author":"Reynolds","year":"2017","journal-title":"Viruses"},{"key":"B95","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ijid.2022.11.020","article-title":"The clinical presentation of monkeypox: A retrospective case-control study of patients with possible or probable monkeypox in a west london cohort","volume":"126","author":"Rimmer","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"B96","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40265-022-01742-y","article-title":"Prevention and treatment of monkeypox","volume":"82","author":"Rizk","year":"2022","journal-title":"Drugs"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1121580","DOI":"10.3389\/fphar.2023.1121580","article-title":"Evidence synthesis of Chinese medicine for monkeypox: Suggestions from other contagious pox-like viral diseases","volume":"14","author":"Rong","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.3390\/vaccines10122083","article-title":"Potentially asymptomatic infection of monkeypox virus: A systematic review and meta-analysis","volume":"10","author":"Satapathy","year":"2022","journal-title":"Vaccines"},{"key":"B99","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.antiviral.2005.06.001","article-title":"In vitro activity of cycloSal-nucleoside monophosphates and polyhydroxycarboxylates against orthopoxviruses","volume":"67","author":"Sauerbrei","year":"2005","journal-title":"Antivir. Res."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.ophtha.2022.08.013","article-title":"Unilateral blepharoconjunctivitis due to monkeypox virus infection","author":"Scandale","year":"2022","journal-title":"Ophthalmology"},{"key":"B101","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1021\/acs.jpclett.3c00087","article-title":"Identification and investigation of a cryptic binding pocket of the P37 envelope protein of monkeypox virus by molecular dynamics simulations","volume":"14","author":"Sen Gupta","year":"2023","journal-title":"J. Phys. Chem. Lett."},{"key":"B102","doi-asserted-by":"publisher","first-page":"e419","DOI":"10.1111\/tbed.12323","article-title":"The possibility of using the ICR mouse as an animal model to assess antimonkeypox drug efficacy","volume":"63","author":"Sergeev","year":"2016","journal-title":"Transbound. Emerg. Dis."},{"key":"B103","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ijid.2022.11.040","article-title":"The use of antivirals in the treatment of human monkeypox outbreaks: A systematic review","volume":"127","author":"Shamim","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.56305\/001c.37605","article-title":"Inpatient management of monkeypox","volume":"1","author":"Shaw","year":"2022","journal-title":"Brown J. Hosp. Med."},{"key":"B105","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1056\/NEJMp2210125","article-title":"Tecovirimat and the treatment of monkeypox - past, present, and future considerations","volume":"387","author":"Sherwat","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2023.2193998","article-title":"In-silico targeting TMPK from monkey pox virus: Molecular docking analysis, density functional theory studies and molecular dynamic simulation analysis","volume":"1","author":"Sib Tul Hassan Shah","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B107","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/cid\/ciac622","article-title":"Antivirals with activity against monkeypox: A clinically oriented review","volume":"76","author":"Siegrist","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"B108","doi-asserted-by":"publisher","first-page":"106497","DOI":"10.1016\/j.compbiomed.2022.106497","article-title":"Translational vaccinomics and structural filtration algorithm to device multiepitope vaccine for catastrophic monkeypox virus","volume":"153","author":"Singh","year":"2023","journal-title":"Comput. Biol. Med."},{"key":"B109","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.antiviral.2007.06.005","article-title":"Efficacy of N-methanocarbathymidine in treating mice infected intranasally with the IHD and WR strains of vaccinia virus","volume":"76","author":"Smee","year":"2007","journal-title":"Antivir. Res."},{"key":"B110","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1600-0536.2008.01405.x","article-title":"Bibliometrics, dermatology and contact dermatitis","volume":"59","author":"Smith","year":"2008","journal-title":"Contact Dermat."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.jaad.2022.10.043","article-title":"Human monkeypox outbreak: Epidemiological data and therapeutic potential of topical cidofovir in a prospective cohort study","volume":"88","author":"Sobral-Costas","year":"2022","journal-title":"J. Am. Acad. Dermatology"},{"key":"B112","doi-asserted-by":"publisher","first-page":"10636","DOI":"10.1007\/s11030-023-10636-4","article-title":"Identification of FDA-approved drugs with triple targeting mode of action for the treatment of monkeypox: A high throughput virtual screening study","volume":"2023","author":"Srivastava","year":"2023","journal-title":"Mol. Divers."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1112816","DOI":"10.3389\/fimmu.2023.1112816","article-title":"Development of multi-epitope vaccines against the monkeypox virus based on envelope proteins using immunoinformatics approaches","volume":"14","author":"Tan","year":"2023","journal-title":"Front. Immunol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1099\/vir.0.000216","article-title":"Using ICR and SCID mice as animal models for smallpox to assess antiviral drug efficacy","volume":"96","author":"Titova","year":"2015","journal-title":"J. General Virology"},{"key":"B115","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s12281-022-00448-8","article-title":"Current options in the diagnosis and treatment of monkeypox","volume":"16","author":"Torres","year":"2022","journal-title":"Curr. Fungal Infect. Rep."},{"key":"B116","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1345\/aph.17453","article-title":"Iritis associated with intravenous cidofovir","volume":"33","author":"Tseng","year":"1999","journal-title":"Ann. Pharmacother."},{"key":"B117","unstructured":"Monkeypox: Background information2022"},{"key":"B118","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ijid.2022.10.031","article-title":"A severe monkeypox infection in a patient with an advanced HIV infection treated with tecovirimat: Clinical and virological outcome","volume":"125","author":"Viguier","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1080\/14760584.2016.1175305","article-title":"Defending against smallpox: A focus on vaccines","volume":"15","author":"Voigt","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1086\/498155","article-title":"Reemergence of monkeypox: Prevalence, diagnostics, and countermeasures","volume":"41","author":"Weinstein","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"B121","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1177\/0091270002239705","article-title":"Pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis","volume":"43","author":"Wolf","year":"2003","journal-title":"J. Clin. Pharmacol."},{"key":"B122","unstructured":"2023 mpox (monkeypox) outbreak: Global trends"},{"key":"B123","unstructured":"WHO advisory committee on variola virus research"},{"key":"B124","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/OLQ.0000000000001747","article-title":"Tecovirimat use in ambulatory and hospitalized patients with monkeypox virus infection","volume":"50","author":"Wu","year":"2022","journal-title":"Sex. Transm. Dis."},{"key":"B125","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jiph.2022.11.033","article-title":"Designing multi-epitope monkeypox virus-specific vaccine using immunoinformatics approach","volume":"16","author":"Zaib","year":"2023","journal-title":"J. Infect. Public Health"},{"key":"B126","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3390\/tropicalmed7120402","article-title":"Global research trends on monkeypox virus: A bibliometric and visualized study","volume":"7","author":"Zeeshan","year":"2022","journal-title":"Trop. Med. Infect. Dis."},{"key":"B127","doi-asserted-by":"publisher","first-page":"2204151","DOI":"10.1080\/22221751.2023.2204151","article-title":"Mpox multi-antigen mRNA vaccine candidates by a simplified manufacturing strategy afford efficient protection against lethal orthopoxvirus challenge","volume":"2023","author":"Zeng","year":"2023","journal-title":"Emerg. Microbes Infect."},{"key":"B128","doi-asserted-by":"publisher","first-page":"2192815","DOI":"10.1080\/22221751.2023.2192815","article-title":"Rational development of multicomponent mRNA vaccine candidates against mpox","volume":"12","author":"Zhang","year":"2023","journal-title":"Emerg. Microbes Infect."},{"key":"B129","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40779-022-00395-y","article-title":"Monkeypox outbreak: A novel threat after COVID-19?","volume":"9","author":"Zhang","year":"2022","journal-title":"Mil. Med. Res."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1149909\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T04:40:02Z","timestamp":1683261602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1149909\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,5]]},"references-count":129,"alternative-id":["10.3389\/fphar.2023.1149909"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1149909","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,5]]},"article-number":"1149909"}}